HERMAN, MALCOLM

V. BROCK Corresponding Author: PO ZHAO, MINGZHOU GUO Affiliations: Chinese PLA General Hospital; Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute; Oncology Center, Johns Hopkins University Selleckchem Selumetinib Objective: To explore the possibility of DNA damage repair genes methylation as prognostic and chemo-sensitive markers in human gastric cancer. Methods: DNA methylation status of five DNA damage repair genes (CHFR, FANCF, MGMT, MLH1 and RASSF1A) was detected by nested methylation specific PCR in 102 paraffin-embedded gastric cancer samples. Chi-square or Fischer’s exact tests were used for evaluating the relationship of methylation status and clinic-pathological characteristics. Kaplan–Meier method and Cox proportional hazards models were employed to analyze

the association of methylation status with overall survival and chemo-sensitivity. Results: Promoter region hypermethylation was detected in 34.3% (35/102), 21.6% Gemcitabine chemical structure (22/102), 12.7% (13/102), 9.8% (10/102) and 0% (0/102) for CHFR, MLH1, RASSF1A, MGMT, and FANCF genes respectively. No association was found between methylation of CHFR, MLH1, RASSF1A, MGMT or FANCF with gender, age, tumor size, tumor differentiation, lymph node metastasis and TNM stage. In docetaxel treated gastric cancer patients, unsensitive to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95%CI 0.069–0.859, p = 0.028), and the overall survival is longer in CHFR methylated group compared with CHFR unmethylated group (log rank p = 0.036). In oxaliplatin treated gastric cancer patients, unsensitive to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95%CI 1.064–8.394, p = 0.038), and the overall survival is longer in MLH1 unmethylated group compared with MLH1 methylated group (log rank p = 0.046). Conclusion: CHFR is frequently methylated in human gastric cancer and CHFR methylation may serve as docetaxel sensitive marker. MLH1 methylation MCE was related to oxaliplatin unsensitive gastric cancer patients. Key Word(s): 1. CHFR; 2. MLH1; 3. Methylation; 4. Gastric Cancer; Presenting Author: MIN WANG Additional Authors:

SHUO CHEN, YING QING, MINYING LIN, ZHUANGJI LUO, DONG WU, QINGYAN LI, WEI HAN, JIAN CHEN Corresponding Author: MIN WANG Affiliations: Qilu hospital, Shandong university Objective: Sulforaphane (SFN), which is highly enriched in cruciferous vegetables, has been studied for its cancer chemopreventive properties and ability to induce autophagy. UDP-glucuronosyltransferase (UGT) 1A induction is one of the mechanisms responsible for the cancer chemopreventive activity of SFN. Methods: The Caco-2 cells were divided into six experimental groups: the control, SFN, 3-MA, rapamycin, SFN/3-MA and SFN/rapamycin. The viability change of cells were assessed. Western blot was employed to detect the expression of microtubule-associated protein 1 light chain 3 (LC3).

HERMAN, MALCOLM

V. BROCK Corresponding Author: PO ZHAO, MINGZHOU GUO Affiliations: Chinese PLA General Hospital; Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute; Oncology Center, Johns Hopkins University LDE225 Objective: To explore the possibility of DNA damage repair genes methylation as prognostic and chemo-sensitive markers in human gastric cancer. Methods: DNA methylation status of five DNA damage repair genes (CHFR, FANCF, MGMT, MLH1 and RASSF1A) was detected by nested methylation specific PCR in 102 paraffin-embedded gastric cancer samples. Chi-square or Fischer’s exact tests were used for evaluating the relationship of methylation status and clinic-pathological characteristics. Kaplan–Meier method and Cox proportional hazards models were employed to analyze

the association of methylation status with overall survival and chemo-sensitivity. Results: Promoter region hypermethylation was detected in 34.3% (35/102), 21.6% Proteasome inhibitor (22/102), 12.7% (13/102), 9.8% (10/102) and 0% (0/102) for CHFR, MLH1, RASSF1A, MGMT, and FANCF genes respectively. No association was found between methylation of CHFR, MLH1, RASSF1A, MGMT or FANCF with gender, age, tumor size, tumor differentiation, lymph node metastasis and TNM stage. In docetaxel treated gastric cancer patients, unsensitive to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95%CI 0.069–0.859, p = 0.028), and the overall survival is longer in CHFR methylated group compared with CHFR unmethylated group (log rank p = 0.036). In oxaliplatin treated gastric cancer patients, unsensitive to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95%CI 1.064–8.394, p = 0.038), and the overall survival is longer in MLH1 unmethylated group compared with MLH1 methylated group (log rank p = 0.046). Conclusion: CHFR is frequently methylated in human gastric cancer and CHFR methylation may serve as docetaxel sensitive marker. MLH1 methylation 上海皓元医药股份有限公司 was related to oxaliplatin unsensitive gastric cancer patients. Key Word(s): 1. CHFR; 2. MLH1; 3. Methylation; 4. Gastric Cancer; Presenting Author: MIN WANG Additional Authors:

SHUO CHEN, YING QING, MINYING LIN, ZHUANGJI LUO, DONG WU, QINGYAN LI, WEI HAN, JIAN CHEN Corresponding Author: MIN WANG Affiliations: Qilu hospital, Shandong university Objective: Sulforaphane (SFN), which is highly enriched in cruciferous vegetables, has been studied for its cancer chemopreventive properties and ability to induce autophagy. UDP-glucuronosyltransferase (UGT) 1A induction is one of the mechanisms responsible for the cancer chemopreventive activity of SFN. Methods: The Caco-2 cells were divided into six experimental groups: the control, SFN, 3-MA, rapamycin, SFN/3-MA and SFN/rapamycin. The viability change of cells were assessed. Western blot was employed to detect the expression of microtubule-associated protein 1 light chain 3 (LC3).

16,17 The two variant alleles, designated as CYP2C9*2 and CYP2C9*3, consist of single-nucleotide substitutions that cause the amino acid changes R144C and I359L, respectively. Both variant alleles lead to decreased enzyme activity on CYP2C9 substrates compared with the wild-type allele. Martinez find more et al.17 demonstrated that

the frequency of CYP2C9 variant alleles was increased in patients with acute bleeding (OR = 1.64, 95% CI = 1.05–2.58; P = 0.02). In another case–control study of 26 patients with NSAID-related upper GI bleeding and 52 controls, setting the CYP2C9*1/*1 wild type as reference, there were significantly higher frequencies of CYP2C9*1/*3 (34.6% vs 5.8%; P < 0.001; Selleck PD 332991 OR = 12.9, 95% CI = 2.9–58) and CYP2C9*1/*2 (26.9% vs 15.4%; P = 0.036; OR = 3.8, 95% CI = 1.1–13) identified in the patients with

bleeding compared to control patients. The presence of the CYP2C9*3 allele was associated with a significantly high risk of bleeding (adjusted OR = 7.3, 95% CI = 2.1–26).16 In contrast, another study from the Netherlands found no association between the CYP2C9 genotype and development of serious NSAID-related ulcers. There are no previous clinical data indicating a significant relationship between polymorphisms of UGT1A6 or CYP2C9 and aspirin-induced peptic ulcer.18 The frequencies of these gene variants in Japanese are less than those in Western populations.12,19–22 In our recent study of low-dose aspirin users, which included 40 patients with peptic ulcer, there was no significant association between these gene variants and peptic ulcer;12,19 however, we could not evaluate bleeding risk because of the small number of subjects, and the number of patients with peptic ulcer was also small. A further large-scale clinical study is required to investigate 上海皓元医药股份有限公司 the association between aspirin-induced ulcer and the genotype of enzymes metabolizing aspirin, especially CYP2C9. Helicobacter pylori and NSAIDs are now recognized as

the two most important etiological factors in peptic ulcer and its complications;23–25 however, the studies report conflicting findings that H. pylori infection increases, has no effect on, or even decreases the risk of NSAID-related ulcers. A meta-analysis of randomized trials (five studies and 939 patients) evaluating whether eradication of H. pylori prevented peptic ulcer in NSAID users suggested that H. pylori eradication reduced the incidence of peptic ulcer in the NSAID-naive patients (OR = 0.26, 95% CI = 0.14–0.49), but not in previously treated patients (OR = 0.95, 95% CI = 0.53–1.72).25 The fact that eradication appears to be effective when performed in NSAID-naive patients is consistent with H. pylori infection having an enhancing effect on NSAID gastrotoxicity or NSAIDs exacerbating H. pylori ulcer or H. pylori ulcerogenesis. We have previously found no association between H.

24 HGF might be a key element in the process leading to improvement of liver cirrhosis because this molecule is a powerful hepatoprotective factor and an inducer of hepatocellular differentiation endowed with antifibrogenic activities.17, 25 HGF strongly inhibits the expression of profibrogenic factors such as TGFβ and CTGF, whereas it activates MMP2, MMP9, and MMP14 and reduces TIMP-1 and TIM-2 expression in different cells (reviewed25). These changes were found in SVIGF-I-treated livers making possible a participation of HGF/c-met induction in the antifibrogenic effect Protease Inhibitor Library price of IGF-I (Figs. 5, 6, Supporting Fig. 3). MMP1, MMP2, and MMP14

act as efficient collagen proteases, which could account for the fibrolysis observed with IGF-I therapy. Reduced activation

of HSCs could also result from decreased expression of PDGF, VEGF, and TGFβ (Fig. 6), which have been involved in activation, proliferation, migration, and increased extracellular matrix deposition from HSCs.14, 15 Therefore, IGF-I may favor resolution of the cirrhotic lesion by activation of fibrolysis and reduction of fibrogenesis. This is similar to what has been described for spontaneous reversion of cirrhosis in rats26 and opposite to the mechanisms involved in cirrhosis progression in humans,27 opening the possibility that IGF-I treatment could also decrease fibrosis progression in patients. Although the presence of cross-linking of collagen can make long-standing liver cirrhosis Pritelivir nmr in humans more difficult to revert than in experimental animals, still IGF-I-based therapy may have a role in these cases as it may exert

hepatoprotective activities, halt fibrogenesis, and partially revert liver fibrosis. Activated HSCs decrease in SVIGF-I-treated livers (Fig. 4). We could not determine with certainty whether activated HSCs undergo apoptosis and/or deactivation. Although we could not clearly detect HSC apoptosis at the time of the sacrifice, this process might have occurred at an earlier timepoint taking into account the marked reduction in fibrous septa observed in SVIGF-I-treated rats. However, as mentioned above, up-regulation of neurotrimin and the presence of vimentin-positive, αSMA-negative cells in the 上海皓元 remaining septa of cirrhotic rats given SVIGF-I argue in favor of HSC deactivation (Supporting Fig. 2). Importantly, IGF-I-based therapy also leads to improvement of liver function probably due to the induction of hepatoprotective factors, such as HGF, together with up-regulation of HNF4α, which stimulates differentiated hepatocellular functions (Fig. 7).20 Up-regulation of HNF4α is paralleled by down-regulation of WT-1 (Fig. 7), a nuclear factor that mediates the loss of differentiated hepatocellular functions.19 WT-1 is up-regulated by TGFβ and it seems possible that the reduction in the expression of this cytokine may contribute to diminish WT-1 and to increase HNF4α abundance.

Statistical analysis with MANOVA. Results: From the multivariate analysis regression, simultaneously Child Turcotte Pugh classification, esophageal varices, ascites, hepatic encephalopathy, haemoglobin, platelet, albumin, sodium, JQ1 potassium, calcium, proteinuria, sex, weight, and age were affecting significantly for the occurrence of hepatorenal syndrome with correlation

within 67% (R = 0.676, P = 0.006). In a partially analysis from the multivariate regression, Child Turcotte Pugh classification (B = 24.743, P = 0.000) is independent factors for affecting the occurrence of hepatorenal syndrome. Conclusion: The Child Turcotte Pugh classification is independent good factor for affecting the occurrence of hepatorenal syndrome. Key Word(s): 1. liver cirrhosis; 2. hepatorenal syndrome; 3. Child Turcotte Pugh Presenting Author: MICHIO KOGAME Additional Authors: MIE SHINOHARA, KOJI ISHII,

MASAO SHINOHARA, TAKASHI IKEHARA, HIDENARI NAGAI, MANABU WATANABE, YOSHINORI IGARASHI, YASUKIYO SUMINO Corresponding Author: MICHIO KOGAME Affiliations: Toho University School of Medicine, Jcho Tokyo Kamata Medical Center, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine Objective: Genetic variation in the interleukin 28B (IL-28B) region is this website known to be associated with sustained virological response (SVR) to pegylated (PEG)-interferon (IFN)-alpha and ribavirin (RBV) in patients having chronic hepatitis C (CHC) genotype 1b and high

viral load. The SVR rate in Japan was recently shown to be approximately 80∼90% in patients with the IL-28B responder genotype, and only 50% in patients with the IL-28B non-responder genotype when they were treated with a new protease inhibitor combined with PEG-IFN plus RBV (new triple therapy). The aim of this study was to clarify the efficacy of low-dose and long-term administration of PEG-IFN-alpha 2a in CHC patients who failed to obtain SVR by prior PEG-IFN plus RBV combination therapy. Methods: Sixteen CHC patients (average: 61, range: 43–80 years, male/female = 10/6) infected with high 上海皓元 viral loads of genotype 1b hepatitis C virus (HCV), who had received PEG-IFN plus RBV therapy for a median 48 (range: 24–96) weeks but had not obtained SVR, were examined in this study. Patients were divided into 3 groups based on the results of the previous PEG-IFN plus RBV regimen: a relapse group (n = 6; serum hepatitis C virus (HCV)-RNA was undetectable by RT-PCR during therapy, but patients became positive less than 24 weeks after the termination of therapy), a break-through group (n = 4; serum HCV-RNA was undetectable by RT-PCR, but patients became positive during therapy), and a null group (n = 6; serum HCV-RNA was detected by RT-PCR during therapy).

Statistical analysis with MANOVA. Results: From the multivariate analysis regression, simultaneously Child Turcotte Pugh classification, esophageal varices, ascites, hepatic encephalopathy, haemoglobin, platelet, albumin, sodium, Selleckchem MK0683 potassium, calcium, proteinuria, sex, weight, and age were affecting significantly for the occurrence of hepatorenal syndrome with correlation

within 67% (R = 0.676, P = 0.006). In a partially analysis from the multivariate regression, Child Turcotte Pugh classification (B = 24.743, P = 0.000) is independent factors for affecting the occurrence of hepatorenal syndrome. Conclusion: The Child Turcotte Pugh classification is independent good factor for affecting the occurrence of hepatorenal syndrome. Key Word(s): 1. liver cirrhosis; 2. hepatorenal syndrome; 3. Child Turcotte Pugh Presenting Author: MICHIO KOGAME Additional Authors: MIE SHINOHARA, KOJI ISHII,

MASAO SHINOHARA, TAKASHI IKEHARA, HIDENARI NAGAI, MANABU WATANABE, YOSHINORI IGARASHI, YASUKIYO SUMINO Corresponding Author: MICHIO KOGAME Affiliations: Toho University School of Medicine, Jcho Tokyo Kamata Medical Center, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine Objective: Genetic variation in the interleukin 28B (IL-28B) region is Anti-infection Compound Library mouse known to be associated with sustained virological response (SVR) to pegylated (PEG)-interferon (IFN)-alpha and ribavirin (RBV) in patients having chronic hepatitis C (CHC) genotype 1b and high

viral load. The SVR rate in Japan was recently shown to be approximately 80∼90% in patients with the IL-28B responder genotype, and only 50% in patients with the IL-28B non-responder genotype when they were treated with a new protease inhibitor combined with PEG-IFN plus RBV (new triple therapy). The aim of this study was to clarify the efficacy of low-dose and long-term administration of PEG-IFN-alpha 2a in CHC patients who failed to obtain SVR by prior PEG-IFN plus RBV combination therapy. Methods: Sixteen CHC patients (average: 61, range: 43–80 years, male/female = 10/6) infected with high 上海皓元医药股份有限公司 viral loads of genotype 1b hepatitis C virus (HCV), who had received PEG-IFN plus RBV therapy for a median 48 (range: 24–96) weeks but had not obtained SVR, were examined in this study. Patients were divided into 3 groups based on the results of the previous PEG-IFN plus RBV regimen: a relapse group (n = 6; serum hepatitis C virus (HCV)-RNA was undetectable by RT-PCR during therapy, but patients became positive less than 24 weeks after the termination of therapy), a break-through group (n = 4; serum HCV-RNA was undetectable by RT-PCR, but patients became positive during therapy), and a null group (n = 6; serum HCV-RNA was detected by RT-PCR during therapy).

Statistical analysis with MANOVA. Results: From the multivariate analysis regression, simultaneously Child Turcotte Pugh classification, esophageal varices, ascites, hepatic encephalopathy, haemoglobin, platelet, albumin, sodium, http://www.selleckchem.com/products/cx-4945-silmitasertib.html potassium, calcium, proteinuria, sex, weight, and age were affecting significantly for the occurrence of hepatorenal syndrome with correlation

within 67% (R = 0.676, P = 0.006). In a partially analysis from the multivariate regression, Child Turcotte Pugh classification (B = 24.743, P = 0.000) is independent factors for affecting the occurrence of hepatorenal syndrome. Conclusion: The Child Turcotte Pugh classification is independent good factor for affecting the occurrence of hepatorenal syndrome. Key Word(s): 1. liver cirrhosis; 2. hepatorenal syndrome; 3. Child Turcotte Pugh Presenting Author: MICHIO KOGAME Additional Authors: MIE SHINOHARA, KOJI ISHII,

MASAO SHINOHARA, TAKASHI IKEHARA, HIDENARI NAGAI, MANABU WATANABE, YOSHINORI IGARASHI, YASUKIYO SUMINO Corresponding Author: MICHIO KOGAME Affiliations: Toho University School of Medicine, Jcho Tokyo Kamata Medical Center, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine, Toho University School of Medicine Objective: Genetic variation in the interleukin 28B (IL-28B) region is MK-8669 known to be associated with sustained virological response (SVR) to pegylated (PEG)-interferon (IFN)-alpha and ribavirin (RBV) in patients having chronic hepatitis C (CHC) genotype 1b and high

viral load. The SVR rate in Japan was recently shown to be approximately 80∼90% in patients with the IL-28B responder genotype, and only 50% in patients with the IL-28B non-responder genotype when they were treated with a new protease inhibitor combined with PEG-IFN plus RBV (new triple therapy). The aim of this study was to clarify the efficacy of low-dose and long-term administration of PEG-IFN-alpha 2a in CHC patients who failed to obtain SVR by prior PEG-IFN plus RBV combination therapy. Methods: Sixteen CHC patients (average: 61, range: 43–80 years, male/female = 10/6) infected with high 上海皓元 viral loads of genotype 1b hepatitis C virus (HCV), who had received PEG-IFN plus RBV therapy for a median 48 (range: 24–96) weeks but had not obtained SVR, were examined in this study. Patients were divided into 3 groups based on the results of the previous PEG-IFN plus RBV regimen: a relapse group (n = 6; serum hepatitis C virus (HCV)-RNA was undetectable by RT-PCR during therapy, but patients became positive less than 24 weeks after the termination of therapy), a break-through group (n = 4; serum HCV-RNA was undetectable by RT-PCR, but patients became positive during therapy), and a null group (n = 6; serum HCV-RNA was detected by RT-PCR during therapy).

Our aims were to assess our baseline ability to achieve an aggregate and per patient dispensed to prescribed factor ratio (D:P ratio) of 1 and to evaluate obstacles to achieving unity. We conducted

a retrospective review of the factor products C59 wnt mw dispensed from our 340B pharmacy and the corresponding prescriptions over the 6-month period prior to instituting routine D:P ratio assessment. The mean D:P ratio for all 65 patients was 1.00 (SD = 0.07). The mean paediatric D:P ratio differed from unity (P = 0.017) and from the mean adult D:P ratio (P = 0.003) in favour of a higher dispensed dose. A correlation between lighter patients and a higher dispensed dose was observed. Also, paediatric patients receiving 2 vials per dose had a mean D:P ratio greater than unity (P = 0.002). Pharmacy size does not dictate the ability to achieve a D:P ratio of unity. Ongoing Fulvestrant concentration monitoring of D:P ratios and dose ranges prescribed should be performed by all pharmacies to ensure acceptable allocation and cost of factor

replacement for each patient. To further improve the D:P ratio metric in the paediatric population manufacturers should strongly consider adding more nominal dose increments within their lower range of vial sizes. “
“Summary.  The efficacy of highly purified VWF/FVIII concentrates with standardized ristocetin cofactor content (VWF:RCo) has been already proven in patients with von Willebrand’s disease (VWD). Aim of this retrospective study is to confirm efficacy and

safety of two highly purified, doubly virus-inactivated VWF/FVIII concentrates in a large cohort of patients with VWD who were characterized at enrolment by bleeding severity score. Study drugs Alphanate or Fanhdi were given to 120 cases (51 males, 69 females, median age 50 years, range 6–83 years). Patients had VWD3 (10), VWD2A (19), VWD2B (25), VWD2M (10) and DDAVP-unresponsive VWD1 (56) and a median bleeding severity score 上海皓元医药股份有限公司 of 8 (range 0–27). A total of 114 bleeding episodes in 55 cases and 131 surgical procedures in 85 cases could be analysed. Excellent-good clinical responses were seen in 97% of bleeding episodes and in 99% of surgical procedures. To prevent recurrent gastrointestinal (GI) bleeding, cerebral (CNS) haemorrhage, haemarthroses, urogenital or multisite bleeding in more severe patients, secondary prophylaxis was also carried out in 15 cases with VWD3 (3), VWD2A (3), VWD2B (2), VWD1 (7). A median dose of 42 IU VWF:RCo kg−1 given every other day or twice a week over a median period of 334 days (range 24–799) prevented bleeding completely in 13 cases and reduced its incidence in the remaining two. These results confirm the efficacy and safety of the study concentrates, not only in the management of bleeding and surgery but also in secondary prophylaxis of severe VWD.

Pathological diagnosis were obtained after surgery and endoscopy detection. Results: 87 lesions were located in duodenal bulb (43.7%). Other lesions were located in descending potion (56.3%). After EUS, 42 cases were diagnosed as cyst, 39 as Brunner’s adenoma, 23 as minor papilla, 19 as lipoma, 18 as polyp, 11 as ectopic pancreas, 10 as stromal tumour, 5 as malignant tumour, 3 as neuroendocrine tumour (carcinoid click here tumour), 2 elevated lesions were pressured by outside organs, another 27 lesions

had no diagnosis. Endoscopic therapy were carried in 48 patients, surgery in 12 patients, endoscopic follow-up in 33 patients from 3 months to 22 months. The diagnostic accuracy of EUS was 83.8% (78/93). Conclusion: EUS can clearly expose five layers of gastrointestinal tract and histological structure of adjacent organs, which is of great help to achieve definite diagnosis of elevated lesions in duodenal GSK3235025 ic50 tract. Key Word(s): 1. Endoscopic; 2. EUS; 3. duodenal; Presenting Author: ZENGDIAN CHEN Additional Authors: CHENGDANG WANG Corresponding Author: ZENGDIAN CHEN, CHENGDANG WANG Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Fujian Medical University Objective: To preliminary study the colonoscopy outcome and clinical symptoms of

the inspectors who was lacking of warning signs and to verify the value and necessity of colonoscopy in it. Methods: Colonoscopy of 4304 patients from Jan. 2006 to Dec. 2011 were reviewed, according to the definition of lower digestive tract symptoms lacking of warning signs. It was a retrospective case study. Results: In all the 4304 patients, the male/female ration was 1:1.14, with average age 48.0 ± 13.5 years old. And it was the most common between 3 to 12 months. 82.1% of the outcome was negative. Comparing the outcomes concluding

symptom association lesions, symptom independent lesions and negative cases, it showed that females who was younger than 40 years with more than 3 months course were common in negative group. Moreover, in organic lesion cases, it could find that the male patients less than 3 month course were more common than ones more than 12 month course. 215 cases were diagnosed as colorectal cancer, and it was 5.0% 上海皓元 of all inspectors. Cases with less than 40 years were 24, between 40 to 60 years were 82 and more than 60 were 109. They was 1.9%, 3.8% and 11.8% respectively of the corresponding age group. Conclusion: It showed that the clinical symptoms were not the influent factor of the colonoscopy in those inspectors lacking of warning signs. However, the risk factors of the colorectal cancer included sex (male), age (>60) and course (<3 month). What’s more, the cancer relevance ratio was positive correlation with age. In a word, it was the first choice to use colonoscopy to inspect lower digestive tract, especially for those more than 60 year old. Key Word(s): 1. Colonoscopy; 2. Screening; 3. Organic lesion; 4.

Pathological diagnosis were obtained after surgery and endoscopy detection. Results: 87 lesions were located in duodenal bulb (43.7%). Other lesions were located in descending potion (56.3%). After EUS, 42 cases were diagnosed as cyst, 39 as Brunner’s adenoma, 23 as minor papilla, 19 as lipoma, 18 as polyp, 11 as ectopic pancreas, 10 as stromal tumour, 5 as malignant tumour, 3 as neuroendocrine tumour (carcinoid Ipilimumab tumour), 2 elevated lesions were pressured by outside organs, another 27 lesions

had no diagnosis. Endoscopic therapy were carried in 48 patients, surgery in 12 patients, endoscopic follow-up in 33 patients from 3 months to 22 months. The diagnostic accuracy of EUS was 83.8% (78/93). Conclusion: EUS can clearly expose five layers of gastrointestinal tract and histological structure of adjacent organs, which is of great help to achieve definite diagnosis of elevated lesions in duodenal this website tract. Key Word(s): 1. Endoscopic; 2. EUS; 3. duodenal; Presenting Author: ZENGDIAN CHEN Additional Authors: CHENGDANG WANG Corresponding Author: ZENGDIAN CHEN, CHENGDANG WANG Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Fujian Medical University Objective: To preliminary study the colonoscopy outcome and clinical symptoms of

the inspectors who was lacking of warning signs and to verify the value and necessity of colonoscopy in it. Methods: Colonoscopy of 4304 patients from Jan. 2006 to Dec. 2011 were reviewed, according to the definition of lower digestive tract symptoms lacking of warning signs. It was a retrospective case study. Results: In all the 4304 patients, the male/female ration was 1:1.14, with average age 48.0 ± 13.5 years old. And it was the most common between 3 to 12 months. 82.1% of the outcome was negative. Comparing the outcomes concluding

symptom association lesions, symptom independent lesions and negative cases, it showed that females who was younger than 40 years with more than 3 months course were common in negative group. Moreover, in organic lesion cases, it could find that the male patients less than 3 month course were more common than ones more than 12 month course. 215 cases were diagnosed as colorectal cancer, and it was 5.0% MCE of all inspectors. Cases with less than 40 years were 24, between 40 to 60 years were 82 and more than 60 were 109. They was 1.9%, 3.8% and 11.8% respectively of the corresponding age group. Conclusion: It showed that the clinical symptoms were not the influent factor of the colonoscopy in those inspectors lacking of warning signs. However, the risk factors of the colorectal cancer included sex (male), age (>60) and course (<3 month). What’s more, the cancer relevance ratio was positive correlation with age. In a word, it was the first choice to use colonoscopy to inspect lower digestive tract, especially for those more than 60 year old. Key Word(s): 1. Colonoscopy; 2. Screening; 3. Organic lesion; 4.